Inogen (NASDAQ:INGN) Stock Rating Upgraded by StockNews.com

Inogen (NASDAQ:INGN - Get Free Report) was upgraded by research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued on Monday.

Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research note on Thursday, January 30th.

Inogen Stock Down 0.6 %

NASDAQ INGN traded down $0.06 during trading hours on Monday, reaching $10.60. The company's stock had a trading volume of 317,491 shares, compared to its average volume of 254,816. Inogen has a 1 year low of $5.82 and a 1 year high of $13.33. The firm's 50-day moving average price is $10.02 and its 200-day moving average price is $10.22. The company has a market capitalization of $252.42 million, a price-to-earnings ratio of -4.71 and a beta of 1.02.

Hedge Funds Weigh In On Inogen

Several large investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its position in shares of Inogen by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company's stock valued at $245,000 after purchasing an additional 1,318 shares during the last quarter. Invesco Ltd. increased its position in shares of Inogen by 2.0% during the 4th quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company's stock valued at $717,000 after purchasing an additional 1,545 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Inogen by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock valued at $128,000 after purchasing an additional 3,031 shares during the last quarter. AlphaQuest LLC bought a new position in Inogen in the 4th quarter valued at $43,000. Finally, American Century Companies Inc. grew its position in Inogen by 10.2% in the 4th quarter. American Century Companies Inc. now owns 54,856 shares of the medical technology company's stock valued at $503,000 after acquiring an additional 5,089 shares during the last quarter. Institutional investors own 89.94% of the company's stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.